Evidence map›Paper›PMID 30814488›Full record

ArticleCell death & disease2019

S1PR1 regulates the switch of two angiogenic modes by VE-cadherin phosphorylation in breast cancer.

Shuang Liu, Chunsheng Ni, Danfang Zhang, Huizhi Sun, Xueyi Dong, Na Che, Xiaohui Liang, Chen Chen, Fang Liu, Jingru Bai and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 53 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. S1PR1 suppresses lung adenocarcinoma progression through p-STAT1/miR-30c-5 p/FOXA1 pathway.Journal of experimental & clinical cancer research : CR · 2024
    Article
  7. Review
  8. TiOJournal of nanobiotechnology · 2023
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. TargetingCancers · 2021
    Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Shuang LiuDepartment of Pathology, Tianjin Medical University, Tianjin, China.
Chunsheng NiDepartment of Pathology, Tianjin Medical University, Tianjin, China.
Danfang ZhangDepartment of Pathology, Tianjin Medical University, Tianjin, China.
Huizhi SunDepartment of Pathology, Tianjin Medical University, Tianjin, China.
Xueyi DongDepartment of Pathology, Tianjin Medical University, Tianjin, China.
Na CheDepartment of Pathology, Tianjin Medical University, Tianjin, China.
Xiaohui LiangDepartment of Pathology, Tianjin Medical University, Tianjin, China.
Chen ChenDepartment of Pathology, Tianjin Medical University, Tianjin, China.
Fang LiuDepartment of Pathology, Tianjin Medical University, Tianjin, China.
Jingru BaiDepartment of Pathology, Tianjin Medical University, Tianjin, China.
Xian LinDepartment of Pathology, Tianjin Medical University, Tianjin, China.
Xiulan ZhaoDepartment of Pathology, Tianjin Medical University, Tianjin, China. xiulanzhao@aliyun.com.
Baocun SunDepartment of Pathology, Tianjin Medical University, Tianjin, China. baocunsun@aliyun.com.
Tianjin Medical University · CNTianjin Medical University General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiogenesis in solid tumors is divided into two modes: endothelium-dependent vessel (EDV) and vasculogenic mimicry (VM). Sphingosine-1-phosphate receptor 1 (S1PR1) plays a vital role on EDV in a variety of human tumors. However, the relationship between S1PR1 and VM is not clear. The aim of this study is to investigate S1PR1 on the regulation of EDV and mimicry formation in breast cancer. Here we show that S1PR1 phosphorylates the complex of VE-cadherin to regulate the switch of EDV and mimicry formation. Suppression of S1PR1 impairs EDV, but contributes to the generation of VM, invasion, and metastasis in vivo and vitro. By inhibiting RhoA activation, the S1PR1/VE-cadherin signaling is blocked. S1PR1 controls VE-cadherin expression and EDV via RhoA activation. Moreover, the low expression of S1PR1 correlates with VM and poor prognosis in breast cancer patient. The results show that S1PR1 regulated RhoA activation to accelerate VE-cadherin phosphorylation (Y731), leading to increased EDV and reduced VM in breast cancer. S1PR1 may provide a new thinking direction for antiangiogenic therapy for patients with breast cancer.

Indexed as

AnimalsAntigens, CDBreast NeoplasmsCadherin 5CadherinsCell Line, TumorCell ProliferationFemaleHEK293 CellsHeterograftsHumansHuman Umbilical Vein Endothelial CellsMCF-7 CellsMiceMice, Inbred BALB CMice, NudeAntigens, CDCadherin 5CadherinsrhoA GTP-Binding ProteinRHOA protein, humanS1PR1 protein, humanSphingosine-1-Phosphate Receptors

Identifiers

PMID30814488
PMCPMC6393557
OpenAlexW2915837329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.